Cediranib (AZD2171)

• CAT Number: I002992
• CAS Number: 288383-20-0
• Molecular Formula: C₂₅H₂₇FN₄O₃
• Molecular Weight: 450.51
• Purity: ≥95%
• Target: VEGFR
• Solubility: DMSO: ≥ 49 mg/mL
• Storage: 3 years -20℃ powder
• IC50: 0.5 nM (VEGFR2); 5 nM/≤3 nM(Flt1/4)
• IUPAC Name: 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
• InChI: InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
• InChIKey: XXJWYDDUDKYVKI-UHFFFAOYSA-N
• SMILES: CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5

Cediranib (Cat.No:I002992), also known as AZD2171, is an orally administered, small molecule inhibitor of multiple tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-kit. It has shown potential in inhibiting angiogenesis and tumor growth in preclinical studies. Cediranib has been investigated in clinical trials for the treatment of various types of cancer, including ovarian cancer, non-small cell lung cancer, and breast cancer.

Reference

[1]. Wedge SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res, 2005, 65(10), 4389-4400.
[2]. Morton CL, et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr Blood Cancer, 2012, 58(4), 566-571.